Inlexisertib

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameInlexisertib
Drug Alias Namemutant RAS cancer therapyDCC-3116
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAutophagy-related protein-1 homolog inhibitorsAutophagy inhibitorsUnc-51 Like Autophagy Activating Kinase 2 inhibitors
TargetsAutophagy-related protein-1 homologUnc-51 Like Autophagy Activating Kinase 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGastrointestinal Stromal Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPortugalNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDeciphera
China Registration ClassN/A

Develop Information

Active CompaniesDeciphera Pharmaceuticals Llc
Inactive CompaniesN/A
Active IndicationsGastrointestinal Stromal Tumors
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A